CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −564 | $28.65 | $16K | 124,228 |
| 2024-03-01 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −9,311 | 0 | ||
| 2024-02-29 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +5,520 | $5.54 | $31K | 568,991 |
| 2024-02-29 | Brumm Joshua T CEO & President | Sale 10b5-1 | −5,520 | $27.50 | $152K | 563,471 |
| 2024-02-29 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −5,520 | 102,343 | ||
| 2024-02-29 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +4,268 | $0.73 | $3K | 147,886 |
| 2024-02-29 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −4,268 | $27.50 | $117K | 143,618 |
| 2024-02-29 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −4,268 | 24,260 | ||
| 2024-02-29 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise 10b5-1 | +3,429 | $1.03 | $4K | 127,657 |
| 2024-02-29 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −3,429 | $27.50 | $94K | 124,228 |
| 2024-02-29 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −3,429 | 9,311 | ||
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −152,244 | $24.83 | $3.8M | 5,700,521 |
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −2,430 | $25.25 | $61K | 5,698,091 |
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −22,567 | $24.83 | $560K | 1,488,486 |
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −360 | $25.25 | $9K | 1,488,126 |
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −13,109 | $24.83 | $325K | 864,697 |
| 2024-02-28 | Rhodes Jason P Director | Sale 10b5-1 | −210 | $25.25 | $5K | 864,487 |
| 2024-02-28 | Atlas Venture Fund XI, L.P. 10% owner | Sale 10b5-1 | −152,244 | $24.83 | $3.8M | 5,700,521 |
| 2024-02-28 | Atlas Venture Fund XI, L.P. 10% owner | Sale 10b5-1 | −2,430 | $25.25 | $61K | 5,698,091 |
| 2024-02-28 | Atlas Venture Fund XI, L.P. 10% owner | Sale 10b5-1 | −22,567 | $24.83 | $560K | 1,488,486 |
Page 23 of 29 · 561 trades